Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies

Expert Opin Investig Drugs. 2024 Feb;33(2):73-77. doi: 10.1080/13543784.2024.2309873. Epub 2024 Jan 26.

Affiliations

¹ Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
² Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Italy.
³ Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
⁴ Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

PMID: 38264792
DOI: 10.1080/13543784.2024.2309873

No abstract available

Keywords: BCL2 inhibitors; BGB-11417; Sonrotoclax; lymphoid malignancies; myeloid malignancies.

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Hematologic Neoplasms* / drug therapy
Hematologic Neoplasms* / pathology
Humans
Proto-Oncogene Proteins c-bcl-2

Substances

Antineoplastic Agents
Proto-Oncogene Proteins c-bcl-2
BCL2 protein, human